Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Crossref DOI link: https://doi.org/10.1158/1078-0432.CCR-16-2561
Published Online: 2017-08-14
Published Print: 2017-08-15
Update policy: https://doi.org/10.1158/crossmark_policy
Bihani, Teeru
Patel, Hitisha K.
Arlt, Heike
Tao, Nianjun
Jiang, Hai
Brown, Jeffrey L.
Purandare, Dinesh M.
Hattersley, Gary
Garner, Fiona